Altered fractionation: Limited by mucosal reactions?

Radiotherapy and Oncology

Volumn 50, Issue 3, 1999, Pages 247-260

  Kaanders, Johannes H A M ^a   Van Der Kogel, Albert J ^a   Kian Ang, K ^b  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Fractionation; Head and neck; Mucositis; Radiotherapy

Indexed keywords

CANCER RADIOTHERAPY; DOSIMETRY; HEAD CANCER; HUMAN; MUCOSA INFLAMMATION; NECK CANCER; NONHUMAN; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION DEPTH DOSE; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; REVIEW; TREATMENT PLANNING;

ANIMALS; CELL HYPOXIA; DOSE FRACTIONATION; HEAD AND NECK NEOPLASMS; HUMANS; INFLAMMATION; MUCOUS MEMBRANE; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY DOSAGE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0032948788     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(99)00012-2     Document Type: Review

References (89)

1. Ang K.K., Landuyt W., Xu F.X., Vanuytsel L., Van der Schueren E. The effect of small radiation doses per fraction on mouse lip mucosa assessed using the concept of partial tolerance. Radiother. Oncol. 8:1987;79-86.
2. Ang K.K., Trotti A., Garden A.S., et al. Overall time factor in postoperative radiation: results of a prospective randomized trial. Radiother. Oncol. 40:(Suppl. 1):1996;S30.
3. Ang K.K., Xu F.X., Landuyt W., van der Schueren E. The kinetics and capacity of repair of sublethal damage in mouse lip mucosa during fractionated irradiations. Int. J. Radiat. Biol. Oncol. Phys. 11:1985;1977-1983.
4. Ang K.K., Xu F.X., Vanuytsel L., van der Schueren E. Repopulation kinetics in irradiated mouse lip mucosa: the relative importance of treatment protraction and time distribution of irradiations. Rad. Res. 101:1985;162-169.
5. Antognoni P., Bignardi M., Cazzaniga L.F., et al. Accelerated radiation therapy for locally advanced squamous cell carcinomas of the oral cavity and oropharynx selected according to tumour cell kinetics, a phase II multicenter study. Int. J. Radiat. Biol. Oncol. Phys. 36:1996;1137-1145.
6. Bäckström A., Jakobsson P.Å., Littbrand B., Wersäll J. Fractionation scheme with low individual doses in irradiation of carcinoma of the mouth. Acta Radiol. Ther. Phys. Biol. 12:1973;401-406.
7. Barker G., Loftus L., Cuddy P., Barker B. The effects of sucralfate suspension and diphenhydramine syrup plus kaolin-pectin on radiotherapy-induced mucositis. Oral Surg. Oral Med. Oral Pathol. 71:1991;288-293.
8. Bentzen S.M. Potential clinical impact of normal-tissue intrinsic radiosensitivity testing. Radiother. Oncol. 43:1997;121-131.
9. Bentzen S.M., Ruifrok A.C.C., Thames H.D. Repair capacity and kinetics for human mucosa and epithelial tumours in the head and neck: clinical data on the effect of changing the time interval between multiple fractions per day in radiotherapy. Radiother. Oncol. 38:1996;89-101.
10. Bernier J., Thames H.D., Smith C.D., Horiot J.C. Tumor response, mucosal reactions and late effects after conventional and hyperfractionated radiotherapy. Radiother. Oncol. 47:1998;137-143.
11. Bourhis J., Fortin A., Dupuis O., et al. Very accelerated radiation therapy: preliminary results in locally unresectable head and neck carcinomas. Int. J. Radiat. Biol. Oncol. Phys. 32:1995;747-752.
12. Bradley P.J., Morgan D.A.L. Radiotherapy of advanced laryngeal cancer using 3 small fractions daily. Otolaryngol. Head Neck Surg. 104:1991;838-841.
13. Brizel D.M., Albers M.E., Fisher S.R., et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 338:1998;1798-1804.
14. Brown J.M. Evidence for acute hypoxic cells in mouse tumours and a possible mechanism of reoxygenation. Br. J. Radiol. 52:1979;650-656.
15. Bujko K., Skoczylas J.Z., Bentzen S.M., et al. A feasibility study of concomitant boost radiotherapy for patients with cancer of the supraglottic larynx. Acta Oncol. 32:1993;637-640.
16. Coutard H. Roentgen therapy of epitheliomas of the tonsillar region, hypopharynx and larynx from 1920 to 1926. Am. J. Roentgenol. Rad. Therapy. 28:1932;313-331.
17. Cox J.D., Pajak T.F., Marcial V.A., et al. ASTRO plenary: interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: results from Radiation Therapy Oncology Group protocol 8313. Int. J. Radiat. Oncol. Biol. Phys. 20:1991;1191-1195.
18. Cummings B.J., Keane T.J., O'Sullivan B., et al. A prospective randomized trial of hyperfractionated versus conventional once daily radiation for advanced squamous cell carcinomas of the larynx and pharynx. Radiother. Oncol. 40:(Suppl. 1):1996;S30.
19. Delaney G.P., Fisher R.J., Smee R.I., Hook C., Barton M.B. Split-course accelerated therapy in head and neck cancer: an analysis of toxicity. Int. J. Radiat. Oncol. Biol. Phys. 32:1995;763-768.
20. Denham J.W., Hamilton C.S., Simpson S.A., et al. Acute reaction parameters for human oropharyngeal mucosa. Radiother. Oncol. 35:1995;129-137.
21. Denham J.W., Walker Q.J., Lamb D.S., et al. Mucosal regeneration during radiotherapy. Radiother. Oncol. 41:1996;109-118.
22. Dische S., Saunders M.I., Barrett A., Harvey A., Gibson D., Parmar M.K.B. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother. Oncol. 44:1997;123-136.
23. Dixit S., Dvivedi M.S., Rawat M., Gujral M.S. Hyperfractionation in advanced head and neck cancer. Indian J. Med. Sci. 45:1991;176-180.
24. Dobrowsky W. Unconventional fractionation with or without mitomycin C in advanced head and neck cancer. Sem. Radiat. Oncol. 2:1992;45-47.
25. Dörr W. Repopulation in mouse oral mucosa: treatment splits. Radiother. Oncol. 33:1994;139-147.
26. Dörr W., Breitner A., Kummermehr J. Capacity and kinetics of SLD repair in mouse tongue epithelium. Radiother. Oncol. 27:1993;36-45.
27. Dörr W., Kummermehr J. Accelerated repopulation of mouse tongue epithelium during fractionated irradiations or following single doses. Radiother. Oncol. 17:1990;249-259.
28. Dörr W., Weber-Frisch M. Repopulation response of mouse oral mucosa during unconventional radiotherapy protocols. Radiother. Oncol. 37:1995;230-236.
29. Epstein J.B., Stevenson-Moore P., Jackson S., Mohamed J.H., Spinelli J.J. Prevention of oral mucositis in radiation therapy: a controlled study with benzydamine hydrochloride rinse. Int. J. Radiat. Oncol. Biol. Phys. 16:1989;1571-1575.
30. Epstein J.B., Wong F.L. The efficacy of sucralfate suspension in the prevention of oral mucositis due to radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 28:1994;693-698.
31. Fletcher G.H., MacComb W.S., Shalek R.J. Radiation therapy in the management of cancer of the oral cavity and oropharynx. 1962;Charles C. Thomas, Springfield, MO. p. 51.
32. Franzén L., Henriksson R., Littbrand B., Zackrisson B. Effects of sucralfate on mucositis during and following radiotherapy of malignancies in the head and neck region. A double-blind placebo-controlled study. Acta Oncol. 34:1995;219-223.
33. Fu K.K., Clery M., Ang K.K., Byhardt R.W., Maor M.H., Beitler J.J. Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09. Int. J. Radiat. Oncol. Biol. Phys. 32:1995;589-597.
34. Garden A.S., Morrison W.H., Ang K.K., Peters L.J. Hyperfractionated radiation in the treatment of squamous cell carcinomas of the head and neck: a comparison of two fractionation schedules. Int. J. Radiat. Oncol. Biol. Phys. 31:1995;493-502.
35. Geara F.B., Peters L.J., Ang K.K., et al. Comparison between normal tissue reactions and local tumor control in head and neck cancer patients treated by definitive radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 35:1996;455-462.
36. Giri P.G.S., Gemer L.S. Accelerated fractionation radiation therapy for advanced squamous cell carcinoma of the head and neck. South. Med. J. 84:1991;1103-1107.
37. Gonzalez Gonzalez D., Breur K., van der Schueren E. Preliminary results in advanced head and neck cancer with radiotherapy by multiple fractions a day. Clin. Radiol. 31:1980;417-421.
38. Gwozdz J.T., Morrison W.H., Garden A.S., Weber R.S., Peters L.J., Ang K.K. Concomitant boost radiotherapy for squamous carcinoma of the tonsillar fossa. Int. J. Radiat. Oncol. Biol. Phys. 39:1997;127-135.
39. Harari P.M. Adding dose escalation to accelerated hyperfractionation for head and neck cancer: 76 Gy in 5 weeks. Sem. Radiat. Oncol. 2:1992;58-61.
40. Henriksson R., Franzén L., Littbrand B. Effects of sucralfate on acute and late bowel discomfort following radiotherapy of pelvic cancer. J. Clin. Oncol. 10:1992;969-975.
41. Horiot J.C., Bontemps P., van den Bogaert W., et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother. Oncol. 44:1997;111-121.
42. Horiot J.C., Le Fur R., N'Guyen T., et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother. Oncol. 25:1992;231-241.
43. Horiot J.C., Nabid A., Chaplain G., et al. Clinical experience with multiple fractions per day (MFD) in the radiotherapy of head and neck carcinoma. J. Eur. Radiother. 3:1982;79-89.
44. Huilgol N.G., Savithri S., Metha A.R. Discontinuous accelerated fractionation in the treatment of advanced head and neck neoplasms, a preliminary report. Acta Oncol. 32:1993;84.
45. Jackson S.M., Weir L.M., Hay J.H., Tsang V.H.Y., Durham J.S. A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer. Radiother. Oncol. 43:1997;39-46.
46. Johnson C.R., Schmidt-Ullrich R.K., Wazer D.E. Concomitant boost technique using accelerated superfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck. Cancer. 69:1992;2749-2754.
47. Kaanders J.H.A.M., Pop L.A.M., Marres H.A.M., et al. Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer. Radiother. Oncol. 48:1998;115-122.
48. Kaanders J.H.A.M., Pop L.A.M., Marres H.A.M., van der Maazen R.W.M., van der Kogel A.J., van Daal W.A.J. Radiotherapy with carbogen breathing and nicotinamide in head and neck cancer: feasibility and toxicity. Radiother. Oncol. 37:1995;190-198.
49. Kaanders J.H.A.M., van Daal W.A.J., Hoogenraad W.J., van der Kogel A.J. Accelerated fractionation radiotherapy for laryngeal cancer, acute and late toxicity. Int. J. Radiat. Oncol. Biol. Phys. 24:1992;497-503.
50. Kajanti M., Blomqvist C., Lehtonen H., Kouri M., Wiklund T., Holsti L.R. Biweekly dose escalation in curative accelerated hyperfractionation for advanced head and neck cancer: a feasibility study. Int. J. Radiat. Oncol. Biol. Phys. 39:1997;837-840.
51. Karim A.B.M.F., Kralendonk J.H., Njo K.H., Tierie A.H., Hasman A. Radiation therapy for advanced (T3T4N0-N3M0) laryngeal carcinoma: the need for a change of strategy: a radiotherapeutic viewpoint. Int. J. Radiat. Oncol. Biol. Phys. 13:1987;1625-1633.
52. Lamb D.S., Spry N.A., Gray A.J., Johnson A.D., Alexander S.R., Dally M.J. Accelerated fractionation radiotherapy for advanced head and neck cancer. Radiother. Oncol. 18:1990;107-116.
53. Leborgne J.H., Leborgne F., Zubizarreta E., Ortega B., Mezzera J. Corticosteroids and radiation mucositis in head and neck cancer. A double-blind placebo-controlled randomized trial. Radiother. Oncol. 47:1997;145-148.
54. Lievens Y., Haustermans K., Van den Weyngaert D., et al. Does sucralfate reduce the acute side-effects in head and neck cancer treated with radiotherapy? A double-blind randomized trial. Radiother. Oncol. 47:1998;149-153.
55. Lindup R. Multiple fractions in the treatment of head and neck cancer. Clin. Oncol. 4:1992;280-283.
56. Lusinchi A., Lartigau E., Luboinski B., Eschwege F. Accelerated radiation therapy in the treatment of very advanced and inoperable head and neck cancers. Int. J. Radiat. Oncol. Biol. Phys. 29:1994;149-152.
57. Maciejewski B., Skladowski K., Pilecki B., et al. Randomized clinical trial on accelerated 7 days per week fractionation in radiotherapy for head and neck cancer. Preliminary report on acute toxicity. Radiother. Oncol. 40:1996;137-145.
58. MacKay R.I., Niemierko A., Goitein M., Hendry J.H. Potential clinical impact of normal-tissue intrinsic radiosensitivity testing. Radiother. Oncol. 46:1998;215-219.
59. Mak A.C., Morrison W.H., Garden A.S., Ang K.K., Goepfert H., Peters L.J. Base-of-tongue carcinoma: treatment results using concomitant boost radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 33:1995;289-296.
60. Makkonen T.A., Boström P., Vilja P., Joensuu H. Sucralfate mouth washing in the prevention of radiation-induced mucositis: a placebo-controlled double-blind randomized study. Int. J. Radiat. Oncol. Biol. Phys. 30:1994;177-182.
61. Marcial V.A., Pajak T.F., Chang C., Tupchong L., Stetz J. Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (preliminary report) by the Radiation Therapy Oncology Group (RTOG). Int. J. Radiat. Oncol. Biol. Phys. 13:1987;41-47.
62. Medini E., Rao Y., Kim T., Levitt S.H. Radiation therapy for advanced head and neck squamous cell carcinoma using twice-a-day fractionation. Am. J. Clin. Oncol. 8:1985;65-68.
63. Meredith R., Salter M., Kim R., et al. Sucralfate for radiation mucositis: results of a double-blind randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 37:1997;275-279.
64. Nguyen T.D., Panis X., Legros M., Froissart D. Hyperfractionated radiotherapy in advanced squamous cell carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 9:1983;393-395.
65. Nissenbaum M., Browde S., Bezwoda W.R., de Moor N.G., Derman D.P. Treatment of advanced head and neck cancer: multiple daily dose fractionated radiation therapy and sequential multimodal treatment approach. Med. Pediatr. Oncol. 12:1984;204-208.
66. Notter G., Turesson I. Clinical randomized pilot studies on multiple fractions a day. In: Proceedings of Varian's Fourth European Clinic Users Meeting, Malta, May 25-26. 1984;Varian, Switzerland. pp. 64-69.
67. Olmi P., Cellai E., Chiavacci A., Fallai C. Accelerated fractionation in advanced head and neck cancer: results and analysis of late sequelae. Radiother. Oncol. 17:1990;199-207.
68. Overgaard J., Sand Hansen H., Overgaard M., et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85. Radiother. Oncol. 46:1998;135-146.
69. Overgaard J., Sand Hansen H., Overgaard M., et al. Conventional radiotherapy as primary treatment of squamous cell carcinoma of the head and neck. A randomized multicenter study of 5 versus 6 fractions/week - report from the DAHANCA 7 trial. Int. J. Radiat. Oncol. Biol. Phys. 39:1997;188.
70. Parsons J.T., Mendenhall W.M., Stringer S.P., Cassisi N.J., Million R.R. Twice-a-day radiotherapy for squamous cell carcinoma of the head and neck: the University of Florida experience. Head Neck. 15:1993;87-96.
71. Peracchia G., Salti C. Radiotherapy with thrice-a-day fractionation in a short overall time: Clinical experiences. Int. J. Radiat. Oncol. Biol. Phys. 7:1981;99-104.
72. Pinto L.H.J., Canary P.C.V., Araújo C.M.M., Bacelar S.C., Souhami L. Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 21:1991;557-562.
73. Sanchíz F., Millá A., Torner J., et al. Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 19:1990;1347-1350.
74. Sauer R., Wannenmacher M., Brizel D., et al. Randomised phase III trial of radiation ± Ethyol (amifostine) in patients with head and neck cancer. Radiother. Oncol. 48:(Suppl. 1):1998;S181.
75. Schwade J.G., Markoe A.M., Abitbol A.A., et al. Accelerating hyperfractionation for carcinoma of the head and neck. Sem. Radiat. Oncol. 2:1992;51-53.
76. Spijkervet, F.K.L., Irradiation mucositis and oral flora. Reduction of mucositis by selective elimination of oral flora. Thesis, University of Groningen, 1989.
77. Stüben G., Landuyt W., van der Schueren E., van der Kogel A.J., Reijnders A. Estimation of repair parameters in mouse lip mucosa during continuous and fractionated low dose-rate irradiation. Radiother. Oncol. 20:1991;38-45.
78. Stüben G., van der Kogel A.J., van der Schueren E. Biological equivalence of low dose rate to multifractionated high dose rate irradiations: investigations in mouse lip mucosa. Radiother. Oncol. 42:1997;189-196.
79. Svoboda V.H.J. Radiotherapy by several sessions a day. Br. J. Radiol. 48:1975;131-133.
80. Svoboda V.H.J. Accelerated fractionation. The Portsmouth experience 1972-1984. Proceedings of Varian's Fourth European Clinac Users Meeting, Malta, May 25-26. 1984;Varian, Switzerland. pp. 70.
81. Symonds R.P., McIlroy P., Khorrami J., et al. The reduction of radiation mucositis by selective decontamination antibiotic pastilles: a placebo-controlled double-blind trial. Br. J. Cancer. 74:1996;312-317.
82. Teo P.M.L., Kwan W.H., Leung S.F., et al. Early tumour response and treatment toxicity after hyperfractionated radiotherapy in nasopharyngeal carcinoma. Br. J. Radiol. 69:1996;241-248.
83. Thames H.D., Bentzen S.M., Turesson I., Overgaard M., van den Bogaert W. Time-dose factors in radiotherapy: a review of the human data. Radiother. Oncol. 19:1990;219-235.
84. Thomlinson R.H., Gray L.H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer. 9:1955;539-549.
85. Tucker S.L., Geara F.B., Peters L.J., Brock W.A. How much could the radiotherapy dose be altered for individual patients based on a predictive assay of normal-tissue radiosensitivity? Radiother. Oncol. 38:1996;103-113.
86. Van den Bogaert W., van der Schueren E., Horiot J.C., et al. The feasibility of high-dose multiple daily fractionation and its combination with anoxic cell sensitizers in the treatment of head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 8:1982;1649-1655.
87. Van der Schueren E., van den Bogaert W., Vanuytsel L., van Limbergen E. Radiotherapy by multiple fractions per day (MFD) in head and neck cancer: acute reactions of skin and mucosa. Int. J. Radiat. Oncol. Biol. Phys. 19:1990;301-311.
88. Wang C.C., Blitzer P.H., Suit H.D. Twice-a-day radiation therapy for cancer of the head and neck. Cancer. 55:1985;2100-2104.
89. Zackrisson B., Franzén L., Henriksson R., Littbrand B. Tolerance to accelerated fractionation in the head and neck region. Acta Oncol. 33:1994;391-396.